Search / 27 posts tagged IMCL

Before I get to my favorite biotech saga, there are noteworthy, if not newsworthy, press releases out this morning from two takeout targets. Genentech (DNA) put out a statement from the special independent board committee that's been appointed to handle the Roche (RHHBY.PK) buyout offer.

We recently calculated the performance of all US stocks since the open following their most recent earnings reports. This takes out the initial reaction to earnings reports in after-hours and pre-market trading and highlights how investors have treated shares post earnings.

Icahn’s push for superior ImClone (IMCL) price might backfire Posted by: in Latest News Filed under: Deals, Microsoft (MSFT), Yahoo! (YHOO), Bristol-Myers Squibb (BMY), ImClone Systems (IMCL) Bristol-Myers Squibb (NYSE: BMY) has made a $60 a share offer for the part of ImClone (NASDAQ: IMCL) that it does not already own.

I love a little Icahn in the morning. ImClone (IMCL) released a statement Monday morning indicating that the Bristol-Myers Squibb (BMY) offer substantially undervalues the company.

Carl Icahn and friends at ImClone Systems Incorporated (NASDAQ: IMCL) have now formally responded to Bristol-Myers Squibb Company (NYSE: BMY) regarding the... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]

With M&A activity finally going strong within the pharma/biotech markets, we were interested in speaking to Zacks senior pharma & biotech analyst Jason Napodano, CFA about how he sees this latest round of mergers taking shape within the overall drug industry in general. Jason, thanks for joining us today.

This week's list of top performers marks a return of some of our holdings, but mostly because they were disemboweled so cleanly over the past few weeks/month - many are simply bouncing to where they were a few weeks ago. I continue to not see any clear trend in terms of sector - it is sort of a hodge podge, but quite a few "broken" stocks are bouncing.

Bristol Myers Moves for ImClone; Kodak Earnings Fade; Diana Shipping Doubles Earnings; Crude Stumbles Again; Google to Start VC Fund; Primetime Ad Drama; MasterCard Slumps on Less Spending; S&P Says U.S. Car Companies are “Junk” -Bristol-Myers Squibb Co.

Medical & Biotech Analyst Upgrades & Downgrades August 1, 2008 · Filed Under General · Comments Off Omnicare (OCR) Raised to Buy at Jefferies. RehabCare (RHB) Raised to Outperform at Morgan Keegan. Hansen Medical (HNSN) Cut to Neutral at Merriman Curhan Ford. ImClone (IMCL) Cut to Hold at Citigroup.

Once Dumped, ImClone Soars If they only had been more patient investors of ImClone Systems, Martha Stewart and others might have done just fine, and avoided jail time. 01 7:19 August '08 ImClone Systems Incorporated|IMCL|NASDAQ Bristol-Myers Squibb Co|BMY|NYSE Drugs (Pharmaceuticals)